Investor Conference Call

Brisbane, Australia, 11 March 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, will host a conference call on **Thursday 12 March at 10am AEST (Brisbane), 11am AEDT (Sydney/Melbourne)** to provide an update on recent developments and future opportunities. Tony Keating, Managing Director and CEO, will host the call.

Conference call details:

Date: Thursday 12 March

Time: 10am AEST (Brisbane), 11am AEDT (Sydney/Melbourne)

Pre-registration link: https://s1.c-conf.com/diamondpass/10004619-invite.html

Conference ID: 1000 4619

Access: Australia: +61 2 9007 3187
                                 New Zealand: 0800 453 055
                                 China: 4001 200 659
                                 Hong Kong: 800 966 806
                                 Singapore: 800 1012 785
                                 United Kingdom: 0800 051 8245
                                 Canada/United States: 1855 881 1339

Participants will need to provide their name and to ask a question, they will need to dial "*1" (star, 1) on their telephone keypad.

A recording will be available four hours after the end of the call on openbriefing.com.

<div align="center">###</div>

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, pneumonia, bronchiolitis, croup, asthma/reactive airway disease exacerbation, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation, and obstructive sleep apnoea. ResApp's smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the

European Union and TGA approved in Australia. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating	Mr Brian Leedman
CEO and Managing Director	Vice President, Corporate Affairs
+61 430 180 659	+61 412 281 780
tony@resapphealth.com.au	brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.